Cargando…

Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art

Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewandowski, Miłosz, Świerczewska, Zuzanna, Barańska-Rybak, Wioletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147387/
https://www.ncbi.nlm.nih.gov/pubmed/35630620
http://dx.doi.org/10.3390/molecules27103143
_version_ 1784716795136966656
author Lewandowski, Miłosz
Świerczewska, Zuzanna
Barańska-Rybak, Wioletta
author_facet Lewandowski, Miłosz
Świerczewska, Zuzanna
Barańska-Rybak, Wioletta
author_sort Lewandowski, Miłosz
collection PubMed
description Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migraine, hyperhidrosis, urinary incontinence from detrusor overactivity, or cosmetics. However, there are numerous promising reports based on off-label BTX usage, indicating its potential effectiveness in other diseases, which remains unknown to many. Among them, dermatological conditions, such as rosacea, annal fissure, Raynaud phenomenon, hypertrophic scars and keloids, and also hidradenitis suppurativa, are currently being investigated. This article aims to provide a comprehensive update on the off-label use of botulinum toxin in dermatology, based on an analysis and summary of the published literature.
format Online
Article
Text
id pubmed-9147387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91473872022-05-29 Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art Lewandowski, Miłosz Świerczewska, Zuzanna Barańska-Rybak, Wioletta Molecules Review Botulinum toxin (BoNT) is a neurotoxin produced by the Clostridium botulinum bacteria. Among seven different isoforms, only BoNT-A and BoNT-B are commercially used. Currently, botulinum toxin has been indicated by the U.S. Food and Drug Administration in several disorders, among others: chronic migraine, hyperhidrosis, urinary incontinence from detrusor overactivity, or cosmetics. However, there are numerous promising reports based on off-label BTX usage, indicating its potential effectiveness in other diseases, which remains unknown to many. Among them, dermatological conditions, such as rosacea, annal fissure, Raynaud phenomenon, hypertrophic scars and keloids, and also hidradenitis suppurativa, are currently being investigated. This article aims to provide a comprehensive update on the off-label use of botulinum toxin in dermatology, based on an analysis and summary of the published literature. MDPI 2022-05-13 /pmc/articles/PMC9147387/ /pubmed/35630620 http://dx.doi.org/10.3390/molecules27103143 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lewandowski, Miłosz
Świerczewska, Zuzanna
Barańska-Rybak, Wioletta
Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title_full Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title_fullStr Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title_full_unstemmed Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title_short Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art
title_sort off-label use of botulinum toxin in dermatology—current state of the art
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147387/
https://www.ncbi.nlm.nih.gov/pubmed/35630620
http://dx.doi.org/10.3390/molecules27103143
work_keys_str_mv AT lewandowskimiłosz offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart
AT swierczewskazuzanna offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart
AT baranskarybakwioletta offlabeluseofbotulinumtoxinindermatologycurrentstateoftheart